Objective: Response to typical antipsychotic medication has been associated with achieving a level of striatal dopamine D 2 receptor occupancy in the range of 65% to 70%. We undertook this study to determine whether response to the atypical antipsychotic olanzapine occurs at lower levels of D 2 receptor occupancy.
A ll currently available antipsychotic medications share the property of blocking dopamine D 2 receptors (1). Further, their relative antipsychotic potencies correlate well with their binding affinities with D 2 receptors in vitro (2) . These findings have led to the suggestion that there may be a threshold level of D 2 receptor blockade necessary to bring about an antipsychotic response. Early studies failed to demonstrate any relation between the degree of D 2 receptor blockade and clinical response (3) . However, the use of high dosages of typical antipsychotic medication and the resultant ceiling levels of D 2 receptor blockade might have precluded the possibility of demonstrating such an association. In addition, the inclusion of poorly responsive chronically ill subjects likely contributed to the difficulty of demonstrating such a relation. Studies by Nordstrom and others (4) and Kapur and others (5), using more modest dosages of raclopride and haloperidol, respectively, have now provided evidence that clinical response to typical antipsychotics requires blockade of approximately 65% to 70% of dopamine D 2 receptors.
PET studies have demonstrated that clozapine, the classic atypical antipsychotic, has a very low affinity for the D 2 receptor: most clozapine-treated patients have steady-state levels of D 2 receptor blockade in the range of 20% to 60% (6, 7) . Given the increased number of new atypical antipsychotics now available, it has also become important to determine whether response to treatment with these agents might occur at a lower level of D 2 receptor occupancy. Uncontrolled PET studies, comparing different typical and atypical antipsychotics, have demonstrated that standard clinical dosages of the atypical antipsychotics risperidone and olanzapine result in levels of striatal D 2 receptor blockade that are comparable to those observed with low dosages of haloperidol (60% to 80%) (8) (9) (10) . Several SPECT studies, however, have demonstrated that patients who are treated with olanzapine and sertindole may have lower levels of D 2 receptor occupancy than those receiving high dosages of haloperidol (11, 12) . Interpretation of previous studies is limited by methodological considerations: most were uncontrolled, did not randomize patients to different treatment groups, were based mainly on convenience samples, and used higher dosages of haloperidol. This last point is particularly crucial because many previous comparative studies used patients on dosages of haloperidol in the range of 10 mg daily, even though it is now clear that much lower dosages give adequate D 2 receptor occupancies.
Our previous work demonstrated that patients receiving haloperidol for treatment of a first episode of schizophrenia were more likely to respond to treatment if more than 65% of D 2 receptors in the caudate were blocked (5, 13, 14) . Such levels are usually achieved with haloperidol dosages in the range of 2 to 3 mg daily (14) . Beyond this level, the risk of adverse side effects increases, with thresholds of approximately 72% and 78% D 2 receptor occupancy for prolactin elevation and EPS, respectively (5) . Atypical antipsychotic agents have in part become increasingly popular for the treatment of first-episode schizophrenia because the risk of acute neurologic side effects appears to be lower with these medications (15) (16) (17) . However, it is not known whether these agents are able to bring about improvement in these highly responsive patients at lower levels of D 2 receptor occupancy than are required for typical antipsychotics. Alternatively, it may be that equivalent degrees of D 2 receptor blockade are achieved but that other pharmacologic properties (that is affinity for 5-HT 2 or other neuroreceptors) are more relevant in explaining the differences in efficacy and side effects reported with these new medications (1) . Using a randomized, double-blind design, we undertook this study to determine whether patients with a first episode of psychosis respond to the atypical antipsychotic olanzapine at lower levels of D 2 receptor occupancy than are observed with low dosages of haloperidol.
Method
This study was carried out as part of a randomized, double-blind, multicentre trial comparing the acute and long-term efficacy of olanzapine with haloperidol in patients experiencing a first episode of psychosis (18) . Both male and female subjects were considered to be eligible for enrolment if they were aged between 16 and 40 years. The first onset of psychotic symptoms had to have occurred before age 35 years, and psychotic symptoms had to be present for at least 1 month, but no more than 5 years, prior to their entering the study. To be included, subjects were required to meet DSM-IV (19) (20) . In addition, all subjects were required to be rated as having psychotic symptoms of "moderate" intensity on 2 or more of the following PANSS (21) psychosis items: "delusions," "conceptual disorganization," "hallucinatory behaviour," "grandiosity," or "suspiciousness/persecution." Alternatively, they could have a rating of "moderate severe" intensity or greater on one of the items. Only subjects who were rated as "moderately ill" or greater on the CGI severity scale (22) were included.
We excluded subjects if they had received more than 16 cumulative weeks of antipsychotic treatment in their lifetime, had serious unstable medical illnesses, had met DSM-IV criteria for substance dependence within the month prior to study entry, or had received injectable depot neuroleptics within fewer than 3 dosing intervals at the expected time of randomization. We also excluded subjects if they were receiving any medication having primarily CNS activity, with the following exceptions: lorazepam, diazepam, or chloral hydrate for agitation or insomnia; or benztropine, biperiden, or propranolol for EPS or akathisia.
All subjects were recruited from the inpatient and outpatient services of the First Episode Psychosis Program at the Centre for Addiction and Mental Health, an urban teaching hospital fully affiliated with the University of Toronto. The Research Ethics Board of the Centre for Addiction and Mental Health approved the research protocol. The subjects received a complete description of the study and gave written informed consent to participate.
At the Toronto site, 31 patients signed consent for the multicentre treatment study, of whom 18 elected to also participate in the PET protocol. Table 1 summarizes the subjects' demographic and clinical characteristics.
At the time of randomization, 9 subjects were neuroleptic-naive. The remainder underwent a brief washout period ranging from 2 days to 11 days (mean 5.9 days, SD 3.4 days). Patients were randomly assigned to receive 1 capsule daily of either drug (that is, 5 mg olanzapine or 2 mg haloperidol) for the first 2 weeks. After the second week in the trial, the dosage could be increased in a stepwise fashion to a maximum of 3 capsules daily (that is, for olanzapine, an increase from 5 mg to either 7.5 or 10 mg; and for haloperidol, an increase from 2 mg to either 4 or 6 mg). After the sixth week of the study, the dosages could be further increased over the next 6 weeks to a maximum dosage of 20 mg daily for either medication.
We acquired the first PET scan after 6 to 15 days of treatment (mean 10.1 days, SD 2.8 days). We acquired the second PET scan 69 to 84 days after starting treatment (mean 73.0 days, SD 4.3 days). Clinical ratings were carried out following the drug washout period and then weekly for the first 6 weeks and biweekly to the end of week 12. To rate psychopathology, we used the PANSS, which also provided measures of positive and negative symptom severity. We used the SAS to assess EPS (23) and the BARS to assess akathisia (24) . We used prolactin levels determined at the time of randomization and at weeks 2 and 12 to investigate the relation between D 2 receptor occupancy and the change in plasma prolactin levels.
PET scans to estimate dopamine D 2 receptor occupancy were obtained after the injection of 10 mCi of high-specific-activity [ 11 C]raclopride (300 to 1600 Ci/mmol) through the use of a bolus plus infusion protocol and a GEMS 2048-15B head-dedicated PET camera (General Electric Medical Systems, Milwaukee). The methods employed here are identical to those described in previous studies of haloperidol, loxapine, risperidone, olanzapine, quetiapine, and clozapine and have been published in detail before (13) . We obtained an estimate of the dopamine D 2 BP of [ 11 C]raclopride from a ratio of the striatal to the cerebellar activity minus 1, in the 35-to 75-minute time period postinjection. In our laboratory, this method yields a within-subject scan-rescan SD of 6% and is set up to yield a high interrater and intrarater reliability of > 0.95 (measured using the intraclass correlation coefficient).
To calculate dopamine D 2 receptor occupancy, one requires a pretreatment estimate of available dopamine D 2 receptors. We used an age-corrected baseline derived from a separate sample of 12 antipsychotic-naive schizophrenia patients and 15 age-matched normal control subjects, as has been done in previous studies (10) .
Statistical Analyses
We determined change in psychopathology at 2 weeks and at 12 weeks by calculating the difference in PANSS measures at those times, compared with the ratings completed immediately prior to randomization (Visit 2). For each measure, we calculated a percentage change measure by dividing the difference by the rating at Visit 2 and then multiplying by 100. To determine whether change in psychopathology was significant at the 2-week and 12-week points, we compared total PANSS scores, using 2-group Students' t tests. Associations between the level of D 2 receptor occupancy and change in clinical measures were assessed with the Pearson productmoment correlation coefficient. We used Fisher's exact test to determine whether there was a threshold level of D 2 receptor occupancy associated with clinical response.
Results
Of the 18 subjects who participated, 8 were randomized to receive olanzapine, and 10 were randomized to receive haloperidol. For the first 2 weeks of the study, all patients received 1 capsule daily of their respective study medications (that is, olanzapine 5 mg daily or haloperidol 2 mg daily). Dosages were then modified as per the study protocol described above. We rescanned patients after 10 to 12 weeks of treatment. Of the 18 subjects who underwent the first scan, 13 returned for a repeat scan. Six of these subjects were receiving olanzapine, and 7 were receiving haloperidol. Figure 1 shows D 2 receptor occupancy values measured at the first and second PET scans. At the time of the first PET scan, the mean D 2 receptor occupancy level for the 8 patients receiving olanzapine 5 mg daily was 63.4%, SD 7.3%, with a range of 53% to 73%. The 10 patients treated with haloperidol 2 mg daily had a mean D 2 receptor occupancy of 73.0%, SD 6.1%, with a range of 61% to 82%. The percentage of D 2 receptor occupancy was significantly higher in the haloperidol group (t = 3.0, df 16; P < 0.01). At the time of the second PET study, all 6 patients who were rescanned on olanzapine were receiving 10 mg daily; they had a mean D 2 receptor occupancy of 72.0%, SD 5.7%, with a range of 62% to 77%. Patients rescanned on haloperidol (mean 4.4 mg daily, SD 4.8, range 2 to 15 mg daily) had a mean occupancy of 78.7%, SD 7.6%, with a range of 64% to 89%. D 2 receptor occupancies for the 2 groups did not differ significantly following dosage adjustment (t = 1.8, df 11; P = 0.10). Table 1 summarizes clinical measures at baseline. At baseline, the 2 treatment groups did not differ significantly on any of the PANSS measures. We observed significant improvement in psychopathology as measured by the PANSS total score at the 2-week rating in both the olanzapine-treated group (mean change -9.0, SD 14.5) and the haloperidol-treated group (mean change -15.2, SD 14.6). For those who continued through to the 12-week point of the study, we saw significant change for the 6 subjects on olanzapine (mean change -16.7, SD 23.8) and the 7 subjects on haloperidol (mean change -25.0, SD 15.1).
D 2 Receptor Occupancy

Response to Treatment
Of the total 18 subjects studied with PET, 9 had experienced at least 20% improvement on the total PANSS at Week 2. Seven of 9 had D 2 occupancies of 70% or greater, whereas 6 of 9 who had less than 20% improvement had D 2 occupancies of less than 70%. Patients who had at least 70% of their receptors occupied were more likely to have experienced 20% improvement at the 2-week point (Fisher's exact test P = 0.08, 2-tailed); 70% (7/10) of individuals who had at least 70% of D 2 receptors occupied, compared with only 25% (2/8) of patients who had less than 70% of D 2 receptors occupied, experienced 20% improvement (Figure 2 ).
For the total group of 18 patients at 2 weeks, changes in PANSS total, positive symptom, and negative symptom scores were not significantly correlated with D 2 receptor occupancy (r = -0.36, P = 0.14; r = -0.34, P = 0.17; and r = -0.36, P = 0.14, respectively). For the 10 subjects treated with haloperidol, D 2 receptor occupancy was correlated with the change on the PANSS total scores and PANSS negative scores ( r = -0.68, P = 0.03; and r = -0.73, P = 0.02, respectively), but not the PANSS positive scores (r = -0.32, P = 0.36). For the 8 subjects treated with olanzapine, the associations between D 2 receptor occupancy and PANSS total, PANSS positive, and PANSS negative symptoms scores were not statistically significant (r = 0.13, P = 0.76; r = -0.11, P = 0.79; and r = 0.06, P = 0.88, respectively).
At 12 weeks, after dosages had been individually adjusted and all patients had D 2 occupancies of 62% or higher, no associations were found between D 2 receptor occupancy and change in PANSS total, PANSS positive, or PANSS negative scores for the 13 subjects remaining in the study (r = 0.00, P = 0.99; r = 0.17, P = 0.58; r = 0.06, P = 0.86, respectively).
Side Effects
Changes in prolactin levels were comparable for the olanzapine and haloperidol groups at both 2 weeks (mean 0.33 mg/L, SD 0.41, and mean 0.35 mg/L, SD 0.43, respectively) and 12 weeks (mean 0.27 mg/L, SD 0.40 mg/L, and mean 0.40 mg/L, SD 0.40, respectively). Change in prolactin was significantly correlated with D 2 receptor occupancy at 12 weeks (n = 13, r = 0.60, P = 0.03) but not at 2 weeks (n = 18, r = 0.21, P = 0.41). At 12 weeks, this effect was apparent for the 7 subjects treated with haloperidol (r = 0.77, P = 0.04) but not for the 6 subjects treated with olanzapine (r = 0.33, P = 0.52). 
Discussion
This study's results suggest that, in patients receiving treatment for a first episode of psychosis, olanzapine has its antipsychotic effect at approximately the same levels of D 2 receptor occupancy as are achieved with low dosages of haloperidol. Thus, even though olanzapine acts on several neuroreceptors that haloperidol does not act on (for example 5-HT 2 , histamine H 1 , and muscarinic M 1 ), it still requires levels of D 2 receptor occupancy comparable to those achieved with haloperidol to achieve its antipsychotic effect.
The dosages of medication that patients received over the first 2 weeks of the study (olanzapine 5 mg daily or haloperidol 2 mg daily) were not equivalent in the degree to which they occupied D 2 receptors: olanzapine produced lower levels of D 2 receptor occupancy. This is consistent with the recent study by de Haan and others, who used [
]iodobenzamide SPECT to demonstrate that olanzapine at a dosage of 7.5 mg daily resulted in less D 2 occupancy than did haloperidol at a dosage of 2.5 mg daily (25) . To produce levels of D 2 occupancy equivalent to 2 mg daily of haloperidol, we would have required 10 mg daily of olanzapine (10) . The choice of 5 mg daily of olanzapine vs 2 mg daily of haloperidol gave us the opportunity to see whether olanzapine could bring about antipsychotic response at lower levels of D 2 receptor occupancy than are seen with haloperidol at 2 mg daily. Our results suggest that this is not the case. Although there are certainly individuals who respond well to olanzapine at a dosage of 5 mg daily, our data suggest that response is more likely to happen, both with haloperidol and with olanzapine, if the dosage of medication results in peak levels of D 2 receptor occupancy above 70%. Both medications led to mean D 2 occupancies above 70% after dosage adjustment; however, there was a trend for subjects treated with olanzapine to have lower levels of D 2 receptor occupancy, compared with those treated with haloperidol. That this difference was not statistically significant may well be due to the very limited power of the study. However, it cannot be concluded that olanzapine brings about clinical improvement at lower levels of D 2 receptor occupancy than does haloperidol because there was also a trend for the overall level of clinical improvement at 12 weeks to be lower in the olanzapine-treated group.
It should also be noted that, while we do find an association between D 2 receptor occupancy and response in the first 2 weeks, we do not find such a relation at the 12-week mark. This is not surprising because, after the first 2 weeks, the clinicians were free to titrate the dosages individually in each patient to maximize response. This led to an increase in mean D 2 receptor occupancy in both groups, such that most patients in the study were above the putative threshold range for clinical response of 65% to 70% D 2 receptor occupancy. Thus it would seem that D 2 receptor occupancy may be an important first mediator of response but that, once a sufficient level of D 2 receptor occupancy has been reached, the rest of the variance in response is unrelated to the differences in D 2 receptor occupancy. This conclusion is consistent with the previous study by Wolkin and others, in which all patients were titrated to very high levels of D 2 receptor occupancy; as a result, differences in response were not related to D 2 receptor occupancy (3).
Prolactin elevation and EPS are common adverse effects of antipsychotic treatment and are closely linked to the levels of D 2 receptor occupancy achieved (5) . EPS have been observed in individuals treated with haloperidol, as well as with olanzapine and risperidone, when D 2 receptor occupancy reaches the 80% level (5). It was therefore surprising that we did not see a stronger relation between EPS and prolactin elevation and D 2 receptor occupancy. We think this is a function of the restricted dosage range of haloperidol used in our study. While almost all previous clinical studies have shown greater EPS and prolactin elevation with haloperidol, compared with olanzapine (26, 27) , all of them have also used dosages that give rise to a disproportionately higher level of D 2 receptor occupancy with haloperidol than with olanzapine.
Several features make this study unique. They include the use of a randomized, double-blind design and a sample of newly diagnosed patients who would be expected to be highly responsive to treatment. The study is also strengthened by having had all subjects on a fixed dosage of medication during the first 2 weeks of the protocol. Interpretation of this study is, however, limited by the small sample size, the flexible dosage titration allowed in the protocol, and the fact that some participants had received previous antipsychotic treatment. The question of the relative merits of olanzapine vs haloperidol in treating patients with a first episode of psychosis cannot be appropriately addressed with this small study; it is the subject of a previously published paper resulting from this multicentre study (18) .
Olanzapine has an effect on several receptors beyond the D 2 receptor system. Some of these, such as effects on the 5-HT 2 receptors, have been associated with a more beneficial effect on negative symptoms and on aspects of global improvement. In our study, we did not observe a preferential effect of olanzapine on negative symptoms or on total symptom improvement. This study's design relates primarily to the effects of olanzapine and haloperidol on D 2 receptors and is not optimal for assessing clinical effects that may be related to other neuroreceptors. A study design that involves a larger sample, a longer treatment duration, and greater variability in D 2 receptor occupancy and that is controlled across medications would help address this question more definitively.
However, until such a study is done, the present data suggest that haloperidol and olanzapine require similar levels of D 2 receptor occupancy to induce an antipsychotic effect in patients early in the course of their psychotic illness. Résultats : À la première TEP, les 8 patients traités à l'olanzapine avaient des occupations significativement moins élevées des récepteurs D 2 (moyenne 63,4 %, ET 7,3) que celles observées chez les 10 patients traités à l'halopéridol (moyenne 73,0 %, ET 6,1). Quand les patients ont subi de nouveau une tomographie, après ajustement du dosage, les occupations moyennes des récepteurs D 2 étaient supérieures à 70 %, dans les deux groupes. Les occupations des récepteurs D 2 ne différaient pas significativement entre le groupe traité à l'olanzapine (moyenne 72,0 %, ET 5,7) et celui traité à l'halopéridol (moyenne 78,7 %, ET 7,6).
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Conclusions :
Ces résultats suggèrent que chez des patients traités pour un premier épisode psychotique, l'olanzapine a un effet antipsychotique à peu près aux mêmes niveaux d'occupation des récepteurs D 2 que ceux obtenus par de faibles doses d'halopéridol.
